4/A: Heron Therapeutics Director Craig A. Johnson Reports Stock and Option Grants

Director Craig A. Johnson reports acquisition of restricted stock units and stock options in Heron Therapeutics.

Summary

• Craig A. Johnson, a director of Heron Therapeutics, reported changes in beneficial ownership.
• On January 31, 2025, Johnson acquired 17,950 shares of common stock through restricted stock units and 35,900 stock options.
• The restricted stock units vest in full on January 31, 2026, each representing a contingent right to receive one share of common stock.
• The stock options, with an exercise price of $1.7, vest in 12 equal monthly installments starting one month after the grant date and expire on January 31, 2035.
• Following these transactions, Johnson directly owns 83,770 shares of common stock and 35,900 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock and option grants, which doesn't inherently indicate positive or negative sentiment about the company's performance.

Positives

• The acquisition of stock options and restricted stock units by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedules of the stock options and restricted stock units suggest a long-term incentive structure for the director.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and alignment with shareholder interests.

Comparison to Industry Standards

• Stock option grants and restricted stock units are common forms of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar equity-based compensation plans for their executives and directors.
• The vesting schedules and exercise prices are typically structured to incentivize long-term value creation.

Stakeholder Impact

• The transactions reported may have a minor positive impact on shareholder sentiment, as they indicate the director's increased stake in the company's success.

Key Dates